South Korea's food and drug safety ministry released English versions of approvals for several biosimilars, The Korea Herald reported Wednesday.
The ministry approved Samsung Bioepis' Brenzys, a biosimilar of Amgen's Enbrel, and Renflexis, a biosmilar of Johnson & Johnson's Remicade.
Earlier this year, the food and drug safety ministry unveiled English-language approvals for Celltron's Remicade biosimilar Remsima and Herzuma, a biosimilar of Roche's Herceptin.
Other approvals slated for disclosure in English include Celltrion's Trumixa, a biosimilar of Roche's Rituxan, following its authorisation in November.
"We will continue to open up the results of our approval evaluation of Korean biosimilars to aid the launch of the drugs in global markets," the ministry explained.